FDA Authorizes Novavax COVID-19 Vaccine, Adjuvanted Use in Adolescents
On August 19, 2022, Novavax, Inc., announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) received expanded Emergency Use Authorization from the FDA to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in adolescents aged 12 through 17 years. Read more.
|
Phase III Trial of Cannabidiol for Treating EMAS Initiated
Jazz Pharmaceuticals recently announced the initiation of a new phase III trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents with epilepsy with myoclonic-atonic seizures (EMAS). The company’s cannabidiol is not currently approved in the United States or European Union for the treatment of EMAS. Read more.
|